The headquarters holds big data for the development of new anti-cancer drugs, derived from several multi-omics analyses of human malignancies over the past five years.
We evaluate the effectiveness of your candidate drugs and help discover novel anti-cancer agents through our 3D spheroid and organoid technologies.
We identify new targeted therapies tailored to all molecular subtypes of breast cancer.
Our technology can also be applied to evaluate the effectiveness of candidate drugs and identify novel anti-cancer therapies in other cancers (ovarian cancer, kidney cancer, etc.).